Abstract
Liver transplant and resection are preferable for the management of hepatocellular carcinoma, but ultimately, tumor location, biology, and patient condition dictate treatment decisions. At the NCCN 2022 Annual Conference, a panel of experts used 3 case studies to develop an evidence- based approach to the treatment of similar patients with hepatocellular carcinoma. Moderated by Daniel B. Brown, MD, FSIR, the session focused on current research regarding liver-directed and systemic therapy options. Liver transplant and resection are preferable for the management of hepatocellular carcinoma, but ultimately, tumor location, biology, and patient condition dictate treatment decisions. At the NCCN 2022 Annual Conference, a panel of experts used 3 case studies to develop an evidence- based approach to the treatment of similar patients with hepatocellular carcinoma. Moderated by Daniel B. Brown, MD, FSIR, the session focused on current research regarding liver-directed and systemic therapy options.
Cite
CITATION STYLE
Agarwal, R., Matsuoka, L. K., & Brown, D. B. (2022). Liver-Directed and Systemic Therapy Options for Hepatocellular Carcinoma. In JNCCN Journal of the National Comprehensive Cancer Network (Vol. 20). Harborside Press. https://doi.org/10.6004/jnccn.2022.5017
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.